Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Assets (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Current Assets for 16 consecutive years, with $103.4 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 9.06% to $103.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103.4 million through Dec 2025, down 9.06% year-over-year, with the annual reading at $103.4 million for FY2025, 9.06% down from the prior year.
  • Current Assets for Q4 2025 was $103.4 million at Anika Therapeutics, up from $101.6 million in the prior quarter.
  • The five-year high for Current Assets was $177.8 million in Q2 2021, with the low at $99.3 million in Q2 2025.
  • Average Current Assets over 5 years is $148.0 million, with a median of $159.6 million recorded in 2023.
  • The sharpest move saw Current Assets grew 7.66% in 2021, then tumbled 35.92% in 2025.
  • Over 5 years, Current Assets stood at $168.5 million in 2021, then rose by 0.6% to $169.5 million in 2022, then decreased by 3.68% to $163.3 million in 2023, then plummeted by 30.41% to $113.7 million in 2024, then fell by 9.06% to $103.4 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $103.4 million, $101.6 million, and $99.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.